IDH2 and central nervous system cancer: Several studies have reported on non-invasive imaging modalities to predict IDH or TERT promoter mutation status to guide treatment strategies for gliomas from the preoperative stage of the initial clinical diagnosis.27,28 To predict the IDH status of gliomas from preoperative MRI, Choi et al.28 developed a model based on deep learning and radiomics using a fully automated hybrid approach.